The ADA algorithm for combined injectable therapy in type 2 diabetes mellitus changed in 2017, in which basal insulin along with GLP-1 RA was preferred compared to basal plus rapid-acting insulin or two daily doses of premix insulin [35]. This evidence concerns the gene GLP1R and diabetes mellitus.